A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL593 in Healthy Participants and Participants With Frontotemporal Dementia (FTD-GRN)
Clinical trial NCT05262023 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05262023
- Sponsor
- Denali Therapeutics Inc.
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-02-01
- Primary completion
- 2026-12-01
- Enrollment
- 85
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.